Germany · Delayed Price · Currency is EUR Telo Genomics Statistics
Total Valuation
Telo Genomics has a market cap or net worth of EUR 3.10 million. The enterprise value is 2.80 million.
| Market Cap | 3.10M |
| Enterprise Value | 2.80M |
Important Dates
The last earnings date was Monday, November 17, 2025.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 100.43M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +30.48% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 4.01% |
| Owned by Institutions (%) | 0.10% |
| Float | 96.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -189.70 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.69 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.11 |
Financial Position
The company has a current ratio of 0.93
| Current Ratio | 0.93 |
| Quick Ratio | 0.79 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -557.23 |
Financial Efficiency
Return on equity (ROE) is -52,000.65% and return on invested capital (ROIC) is -32,246.03%.
| Return on Equity (ROE) | -52,000.65% |
| Return on Assets (ROA) | -320.71% |
| Return on Invested Capital (ROIC) | -32,246.03% |
| Return on Capital Employed (ROCE) | 10,060.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -98.31% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 44.01 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.64M |
| Pretax Income | -1.66M |
| Net Income | -1.66M |
| EBITDA | -1.64M |
| EBIT | -1.64M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 297,691 in cash and n/a in debt, giving a net cash position of 297,691.
| Cash & Cash Equivalents | 297,691 |
| Total Debt | n/a |
| Net Cash | 297,691 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -16,340 |
| Book Value Per Share | -0.00 |
| Working Capital | -27,568 |
Cash Flow
In the last 12 months, operating cash flow was -1.32 million and capital expenditures -3,258, giving a free cash flow of -1.33 million.
| Operating Cash Flow | -1.32M |
| Capital Expenditures | -3,258 |
| Free Cash Flow | -1.33M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Telo Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.48% |
| Shareholder Yield | -30.48% |
| Earnings Yield | -53.45% |
| FCF Yield | -42.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 0.2.
| Last Split Date | Nov 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |